Key Companies - Hydrocortisone Industry

Hydrocortisone

is a synthetic glucocorticoid that is commonly used to treat a variety of inflammatory and autoimmune conditions. The global hydrocortisone market is expected to grow due to increasing prevalence of inflammatory diseases and rising demand for effective treatment options. However, patent expirations and generic competition are expected to restrain market growth. In addition, side effects associated with hydrocortisone use, such as weight gain and high blood pressure, may limit its adoption. The market is also impacted by factors such as government regulations, reimbursement policies, and availability of alternative treatments. The growing focus on personalized medicine and increasing use of combination therapies are expected to create new opportunities for market players in the coming years.

Top Companies in the Hydrocortisone Industry:

AstraZeneca plc

This British-Swedish multinational pharmaceutical company was founded in 1999 through the merger of Astra AB and Zeneca Group plc. Its headquarters are located in Cambridge, England, and it operates in over 100 countries worldwide. In recent years, AstraZeneca has been in the news for its development of a COVID-19 vaccine in collaboration with the University of Oxford. It has also been involved in numerous mergers and acquisitions, such as the acquisition of Alexion Pharmaceuticals for $39 billion in 2020.

GlaxoSmithKline plc

This British pharmaceutical company was founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. Its headquarters are located in Brentford, England, and it operates in more than 150 countries worldwide. In March, 2023 GSK plc and SCYNEXIS, Inc. announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC). 

Merck & Co. Inc.

This American multinational pharmaceutical company was founded in 1891 and is headquartered in Kenilworth, New Jersey. It operates in over 140 countries worldwide and is known for its development of vaccines, oncology drugs, and cardiovascular drugs. In November, 2021 Merck & Co. Inc. announced that the US Food and Drug Administration (FDA) had granted the company's investigational HIV-1 capsid inhibitor, MK-8718, Breakthrough Therapy designation for the treatment of people living with HIV-1 who have highly resistant strains of the virus.

Pfizer Inc.

This American multinational pharmaceutical company was founded in 1849 and is headquartered in New York City. It operates in over 190 countries worldwide and is known for its development of drugs for a wide range of therapeutic areas, including oncology, cardiology, and immunology. In January, 2023 Gero announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data. 

Sandoz AG (Novartis AG)

This Swiss multinational pharmaceutical company was founded in 1996 as a subsidiary of Novartis AG. Its headquarters are located in Basel, Switzerland, and it operates in over 160 countries worldwide. Sandoz is known for its development of generic drugs and biosimilars, and in recent years, it has been focused on expanding its biosimilars portfolio through acquisitions, such as its acquisition of Aspen Pharmacare's Japanese operations in 2020.

Sanofi S.A

This French multinational pharmaceutical company was founded in 1973 through the merger of Elf Aquitaine and Total S.A.'s pharmaceuticals division. Its headquarters are located in Paris, France, and it operates in over 170 countries worldwide. Sanofi is known for its development of drugs for a wide range of therapeutic areas, including diabetes, cardiovascular diseases, and rare diseases. In recent years, Sanofi has been focused on expanding its oncology portfolio through acquisitions, such as its acquisition of Synthorx for $2.5 billion in 2019.

Actimis Pharmaceuticals

This American biopharmaceutical company was founded in 2004 and is headquartered in San Diego, California. It is focused on the development of drugs for respiratory and inflammatory diseases. In recent years, Actimis has been in the news for its collaboration with Boehringer Ingelheim to develop treatments for chronic obstructive pulmonary disease (COPD).

*Definition-

Hydrocortisone is a synthetic hormone used to treat inflammation and autoimmune diseases. It works by suppressing the immune response and reducing inflammation in the body.